Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Guardant Health, Inc. (GH) Management on Q2 2022 Results - Earnings Call Transcript
11:00pm, Thursday, 04'th Aug 2022
Guardant Health, Inc. (NASDAQ:GH ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy - Co-Chief Executive
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
09:03pm, Thursday, 04'th Aug 2022
Guardant Health (GH) delivered earnings and revenue surprises of -80% and 4.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health: Recent Developments Signal More Upsides
11:31am, Sunday, 31'st Jul 2022
The company recently signed a deal with the premier electronic medical record company, EPIC. Realizing the tremendous value of its business, Guardant acquired all remaining shares from its Joint Ventu
5 Top Stocks Cathie Wood Bought This Week
03:01pm, Friday, 29'th Jul 2022
Despite a 75 basis point interest rate hike by the Federal Reserve, shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ), are up about 7% the past mont
2 Cancer-Focused Stocks That Could Soar, According to Wall Street
11:15am, Wednesday, 13'th Jul 2022
Let's look beyond short-term price targets analysts assign.
Why Shares of Guardant Health Dropped 33.6% in May
12:29pm, Thursday, 02'nd Jun 2022
The biotech company is down more than 61% this year.
Guardant Health to Participate in Upcoming June Investor Conferences
04:05pm, Thursday, 26'th May 2022
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology
Why Guardant Health Stock Is Crashing Today
11:56am, Friday, 06'th May 2022
Investors reacted negatively after the company's Q1 update.
Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance
10:13am, Friday, 06'th May 2022
Guardant Health Inc's (NASDAQ: GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million,
Guardant Health, Inc. (GH) Q1 2022 Results - Earnings Call Transcript
11:50pm, Thursday, 05'th May 2022
Guardant Health, Inc. (NASDAQ:GH ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Alex Kleban - VP, IR Helmy Eltoukhy - Co-CEO AmirAli Talasaz - Co- CEO Mike Bell - CFO C
Guardant Health (GH) Reports Q1 Loss, Lags Revenue Estimates
07:34pm, Thursday, 05'th May 2022
Guardant Health (GH) delivered earnings and revenue surprises of 1.63% and 0.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
This Chart Is Why I'm Not Worried About Guardant Health
06:20am, Thursday, 28'th Apr 2022
The leading innovator in the liquid biopsy space has huge addressable markets ahead of it.
Guardant Health to Report First Quarter Financial Results on May 5, 2022
04:05pm, Wednesday, 13'th Apr 2022
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2022 after marke
Why Guardant Health Stock Soared Nearly 10% Higher Today
04:20pm, Friday, 01'st Apr 2022
Negativity surrounding the precision oncology company might be overblown.
